Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call reveals several positive indicators: a continuing trend of onboarding customers, strategic expansion with a new base in Chicago, and effective cost management strategies like the fuel pass-through mechanism. Despite some uncertainties in SG&A growth and transport distance variability, the overall sentiment from the Q&A is optimistic, supported by growth in transplant industry activity and strategic market expansions. These factors, combined with stable financial metrics, suggest a positive stock price movement in the short term.
Key Financial Performance
Total Revenue $67.4 million in Q1 2026, an 87.4% increase year-over-year from $35.9 million. This growth was driven by organic growth in Logistics (32%) and the addition of the Clinical business.
Logistics Revenue $47.6 million in Q1 2026, a 32.4% increase year-over-year from $35.9 million. Growth was primarily driven by higher Air revenue from both new and existing customers.
Clinical Revenue $19.8 million in Q1 2026, a 12.7% sequential increase from $17.6 million in Q4 2025. Growth was driven by Transplant Clinical revenue, which rose 26.7% sequentially due to NRP and Surgical Recovery services.
Gross Profit $14.1 million in Q1 2026, a 100% increase year-over-year from $7.1 million. This was driven by growth in Logistics and the addition of the Clinical business.
Gross Margin 21% in Q1 2026, an increase of approximately 140 basis points year-over-year from 19.6%. This was due to the positive mix impact from the Keystone acquisition, partially offset by a modest decline in Logistics gross margins.
Logistics Gross Profit $9.2 million in Q1 2026, a 29.9% increase year-over-year from $7.1 million. Logistics gross margin was 19.3%, a slight decrease of 30 basis points year-over-year due to customer mix.
Clinical Gross Profit $5 million in Q1 2026, a 29.2% sequential increase from $3.8 million in Q4 2025. Clinical gross margin rose to 25% from 21.8% sequentially, driven by margin improvement and a mix shift towards Transplant Clinical revenue.
Adjusted SG&A $9.2 million in Q1 2026, a $0.3 million sequential increase from $8.9 million in Q4 2025. The increase was driven by investments in resources and infrastructure to support growth.
Adjusted EBITDA $6.4 million in Q1 2026, a sequential decrease from $7 million in Q4 2025. Adjusted EBITDA margin declined by 90 basis points to 9.5%, driven by a reduction in gross margin and a slight increase in adjusted SG&A.
Operating Cash Flow $3.9 million in Q1 2026. The $2.5 million difference between adjusted EBITDA and operating cash flow was due to $1 million of income statement adjustments and a $1.5 million increase in working capital.
Capital Expenditures $5.5 million in Q1 2026, primarily driven by the $3.7 million acquisition of one aircraft and aircraft capitalized maintenance.
Free Cash Flow (before aircraft and engine acquisitions) $2.1 million in Q1 2026. This was achieved despite non-recurring cash items and the timing of annual incentive compensation payouts.
Cash and Short-term Investments $58.8 million at the end of Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Clinical Business Contribution: The new Clinical business contributed significantly to the 87% year-over-year revenue growth, with a 12.7% sequential increase in revenue to $19.8 million in Q1 2026.
NRP and Surgical Recovery Services: Growth driven by new customer acquisitions and higher volumes within the existing customer base. New NRP services were provided to a new OPO in the Pacific Northwest.
Cross-Sell Opportunities: Several new Transplant Center clinical customers were onboarded, some of which were existing Logistics customers, indicating early cross-sell wins.
Expansion into Midwest: Launched a new combined Logistics and Clinical base in Chicago to serve new transplant center customers and improve cost efficiency for Midwest organ recovery.
Aviation and Logistics Expansion: Acquired one new plane, bringing the total to 10 owned aircraft and 35 dedicated fleet. Opened several new aviation bases, totaling approximately 20 logistics hubs nationwide.
Operational Efficiencies in Transplant Ecosystem: Third-party recovery and NRP adoption have improved efficiency, reducing logistics costs and increasing usable organs per donor.
Improved Cash Flow: Generated operating cash flow of $3.9 million and free cash flow before aircraft acquisitions of $2.1 million in Q1 2026.
M&A Strategy: Acquired Ohio Valley Perfusion Associates for $1 million, expected to contribute $100,000 in adjusted EBITDA for 2026. Pipeline includes both small and larger bolt-on acquisitions.
Regulatory Preparedness: Developing a training pathway for thoracic donor recovery and NRP to meet anticipated certification standards, ensuring scalability and quality.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Decreased donor volumes: The overall number of deceased donors has been reduced following media and regulatory scrutiny in mid-2025. Although there has been sequential improvement, donor levels remain below historical norms, which could impact the company's operations and growth in the transplant ecosystem.
Logistics gross margin variability: Logistics gross margins have been impacted by customer mix, shorter trip lengths, and the types of aircraft used. These factors have led to a decline in gross margins, which could affect profitability.
Regulatory scrutiny on donor surgeon certification: Increased regulatory scrutiny around certification and qualification standards for donor surgeons could pose challenges. The company has designed its recovery service line to be forward-compatible, but this evolution may require additional resources and adjustments.
Dependence on third-party recovery: The shift to third-party surgical recovery is critical for the transplant ecosystem, but it also increases reliance on external surgeons and logistical coordination, which could pose operational risks.
Customer mix shifts: Shifts in customer mix, such as an increase in OPOs with shorter trip lengths, have impacted margins and could continue to create variability in financial performance.
Fuel surcharge variability: Higher-than-anticipated fuel surcharges for the remainder of the year could impact logistics gross margins and overall profitability.
M&A execution risks: The company is pursuing an active M&A strategy, but integrating acquisitions and achieving projected synergies could pose challenges, especially with a mix of smaller and larger acquisitions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company reiterates its 2026 revenue guidance of $260 million to $275 million. For Q2 2026, revenue is expected to increase in the low single digits sequentially.
Adjusted EBITDA Guidance: The company maintains its 2026 adjusted EBITDA guidance of $29 million to $33 million. Adjusted EBITDA margin for Q2 2026 is expected to improve to approximately 10%.
Free Cash Flow Guidance: The company projects free cash flow before aircraft and engine purchases to be between $15 million and $22 million for 2026.
Logistics Gross Margins: Logistics gross margins are expected to remain in the 20% range for the rest of 2026, influenced by factors such as fuel surcharges and customer mix.
Clinical Gross Margins: Clinical gross margins are trending above expectations, with Q1 2026 margins at 25%. While they may not remain at this level each quarter, they are expected to perform strongly.
M&A Strategy: The company plans to continue its M&A strategy, with several opportunities under exclusivity across multiple business lines. These include smaller acquisitions like Ohio Valley Perfusion and larger bolt-ons projected to generate low single-digit millions of adjusted EBITDA annually.
Market Trends in Transplant Industry: The company anticipates continued growth in third-party surgical recovery, NRP, and machine perfusion, which are expected to drive efficiency and growth in the transplant ecosystem.
Regulatory Developments: The company is preparing for increased regulatory scrutiny and certification standards for donor surgeons. It is expanding its pipeline of licensed surgeons and developing a dedicated training pathway for thoracic donor recovery and NRP.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the trend of onboarding Transplant Center Logistics customers as Clinical customers continuing?
A:Yes, the company continues to onboard Transplant Center Logistics customers as Clinical customers. After the Keystone transaction, there was an initial step-up in capturing clinical cases, and while no further big step-ups are expected, the trend benefits the Logistics business as the Clinical business grows.
Q:What impact does adding a new base in Chicago have on growth?
A:The new Chicago base, which combines Clinical and Logistics capabilities, provides flexibility and new capabilities. It allows for standby airplanes, local dispatch of surgeons, and flying out perfusionists and surgeons to other areas. This expansion covers a previously underserved region.
Q:How does the high oil price impact the company's top line and bottom line?
A:The company has a fuel pass-through mechanism in its Logistics contracts, where fuel costs above a certain threshold are passed on to customers with full visibility. The company minimizes costs by strategically locating planes to reduce repositioning flights, so high oil prices have minimal impact on the business.
Q:What criteria does the company use to enter a new market in the U.S.?
A:The company responds to customer needs and aims to offer dedicated capacity with aviation assets. New markets are entered based on customer demand, and resources are relocated to support new customers efficiently. For example, the Chicago hub supports existing customers and will serve new customers later in the year.
Q:Do logistics associated with clinical trials in the transplant space have higher margins or revenue?
A:No, the company does not charge differently based on the medical device used in clinical trials. Their contracts cover 100% of the flying for customers, regardless of the device or clinical trial involvement, so there is no significant impact on margins or revenue.
Q:What are the typical structures for acquisitions in the space?
A:Acquisition structures vary but often include an equity component. The company offers simpler structures compared to private equity, with transparent publicly traded equity. Entrepreneurs appreciate the strategic approach and the opportunity to participate in the upside of the partnership.
Q:What is the company's strategy for expanding organ recovery hubs?
A:The expansion of organ recovery hubs is driven by customer demand. The company places airplanes close to customers to reduce repositioning flights and improve cost efficiency. There is significant opportunity for growth, particularly in the West and Southwest regions.
Q:What caused the modest reduction in average transport distance for organs?
A:The reduction is attributed to normal variability and customer mix in a given quarter. Over time, the distance organs travel has increased due to regulatory changes, and the company expects this trend to continue.
Q:What were the effects of weather during Q1?
A:Unusual weather in Q1 caused airport closures, such as in Peterborough, impacting operations for several days. While transplant centers adjusted schedules to mitigate the impact, there was still some effect on operations.
Q:What is the outlook for SG&A growth for the rest of the year?
A:Adjusted SG&A was $9.2 million in Q1, with a modest sequential increase. The company expects modest growth in SG&A throughout the year to support business growth, including adding staff and infrastructure.
Q:What is the outlook for transplant industry growth this year?
A:Deceased donor activity has improved, leading to a reacceleration of transplant growth to mid-single digits in Q1. This aligns with the company's guidance, and while further recovery in deceased donors could increase transplants, this is not factored into the guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected growth rate of SG&A expenses beyond describing it as 'modest growth.' Additionally, they did not provide a clear explanation for the variability in average transport distance for organs, attributing it to 'customer mix' and 'normal variability' without further elaboration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chicago
Clinical
DCD
Logistics
Midwest
NRP
Ohio Valley
Passenger
acquisition
airplane
area
aviation
base
business
capacity
cash flow
certification
deal
donor organ
donor volume
field
front
industry
leader
level
line
logistics
measure
opportunity
party recovery
perfusion
platform
scale
service
surgeon
transplant center
transplant community
value
SRTA Transcript
Strata Critical Medical, Inc. (SRTA) Q1 2026 Earnings Call Transcript
Positive5-6
The company's earnings call reveals several positive indicators: a continuing trend of onboarding customers, strategic expansion with a new base in Chicago, and effective cost management strategies like the fuel pass-through mechanism. Despite some uncertainties in SG&A growth and transport distance variability, the overall sentiment from the Q&A is optimistic, supported by growth in transplant industry activity and strategic market expansions. These factors, combined with stable financial metrics, suggest a positive stock price movement in the short term.
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call summary shows strong financial performance with a 10% revenue increase and improved gross margins. The company has also raised its revenue guidance, indicating optimism about future growth. Despite risks and uncertainties mentioned, the financial health and growth prospects appear strong, suggesting a positive market reaction.
Strata Critical Medical, Inc. (SRTA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call highlights strong financial performance with record segment adjusted EBITDA and improved margins. The Q&A section reveals positive sentiment from analysts about growth potential, driven by new customer acquisition and market share gains. Despite some concerns about guidance clarity, the overall tone is optimistic, with expectations for continued growth and improved margins. The absence of debt and a healthy cash position further supports a positive outlook.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
